Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by INmune Bio, Inc. INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease September 30, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort September 26, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Disease Trial Demonstrating Correlation between EMACC and CDR-SB Endpoints September 17, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Announces $13.0 Million Registered Direct Offering September 13, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference September 03, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients July 29, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 July 25, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Journal for ImmunoTherapy of Cancer July 23, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial June 27, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. to Join Russell 3000® Index May 30, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9 May 07, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years April 30, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer April 29, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules April 25, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assay April 23, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering April 22, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024 April 08, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28 March 26, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapy March 13, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™ March 05, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 12, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024 February 06, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program January 30, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer January 02, 2024 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA December 18, 2023 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium November 29, 2023 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease November 27, 2023 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe November 15, 2023 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority October 31, 2023 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα October 30, 2023 From INmune Bio, Inc. Via GlobeNewswire Tickers INMB Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.